
WASHINGTON (AP) — The Food and Drug Administration said Friday it will add a new warning and other limitations to a gene therapy for Duchenne’s muscular dystrophy that's been linked to two patient deaths.
The infused therapy from Sarepta Therapeutics will carry a boxed warning — the most serious type — alerting doctors and patients to the risk of potentially fatal liver failure with the treatment, the FDA said in a release.
The one-time therapy, Elevidys, has been under FDA scrutiny since the company reported the first of two deaths of teenage boys in March. Following a second death reported in June, the FDA briefly called for halting all shipments of the drug. But the agency quickly reversed course after facing pushback from patient families and libertarian activists close to President Donald Trump.
Elevidys is the first U.S.-approved gene therapy for Duchenne’s muscular dystrophy, a fatal muscle-wasting disease that affects boys and young men.
In addition to the boxed warning, the FDA is also limiting the drug's approved use to patients who are 4 years old and up and can still walk. Previously the FDA had allowed the drug's use in immobile patients, who generally have more advanced disease.
New labeling will also recommend weekly liver function monitoring for the first three months of treatment, as well as other precautionary steps.
Elevidys is Sarepta's best-selling product and recent headwinds against the drug have weighed heavily on the company and its stock. In July, the Cambridge, Massachusetts-based company announced it would lay off 500 employees.
Sarepta Therapeutics Inc. shares rose 7.7% in trading after the FDA announcement, reflecting improved visibility for investors about the company's outlook.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
LATEST POSTS
- 1
Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026 - 2
'Every day I planned an escape': Ariel Cunio shares details of Hamas captivity - 3
Rediscovering Imagination in Adulthood: Individual Creative Excursions - 4
Iran war drives global fertilizer prices up, raising food cost fears - 5
The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior
Why Tourists May Want To Reconsider Traveling To This Popular Spot In Italy In 2026
IDF: Staying in West Bank refugee camps will quell lone-wolf terror
Vice President Dick Cheney’s life followed the arc of the biggest breakthroughs in cardiovascular medicine
Flourishing in a Cutthroat Work Market: Vocation Methodologies
Tech Patterns 2023: 12 Advancements to Keep an eye Out For
The Difficulties of Getting a Green Card in the US
Fossil analysis changes what paleontologists know about how long T. rex took to grow full size
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
Surprise! Saturn's huge moon Titan may not have a buried ocean after all













